Baricitinib in Pediatric Patients with COVID-19 (I4V-MC-KHAB)

I'm Interested!

A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19

Sex at Birth: Any
Age: Child (Birth - 17)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase III
Conditions Being Studied: COVID-19

Study Purpose

This study is being done to see how safe an investigational drug called baricitinib is and how well it will work to help people with COVID-19. The FDA is allowing the use of this drug for research.

Who Can Participate

Age: 1-18

Principal Investigator
Ankita Desai MD

Department/Division
Pediatrics (Infectious Disease)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: SITE00001555
StudyID: 2021-0726
ClinicalTrials.gov: NCT05074420

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422